Skip to main content
Top
Published in: Breast Cancer Research 2/2006

01-11-2006 | Poster Presentation

Potential role of cyclin D1in DNA damage response

Authors: N Suwaki, DJ Mann

Published in: Breast Cancer Research | Special Issue 2/2006

Login to get access

Excerpt

In mammalian cells, cell cycle progression is governed by distinct cyclin-dependent kinases (cdks) whose activities are regulated by binding of their activating cyclin subunits and through negative regulation by inhibitor proteins such as p21. Cyclin levels oscillate in a phase-dependent manner, ensuring the stage-specific activation of cyclin/cdk complexes. The D-type cyclin levels are thought to act as sensors of the cellular environment: under conditions permissive for proliferation, D-type cyclins accumulate and facilitate the G1 phase progression; whereas under restrictive conditions, D-type cyclin transcription is attenuated and the protein is destabilised via ubiquitin-mediated proteolysis. In addition to the normal cell cycle regulation, a member of D-type cyclins, cyclin D1, has been implicated in the DNA damage response. Once activated, DNA damage responses disrupt the function of the cell cycle and can result in a number of outcomes including short-term or long-term cell cycle arrest, apoptosis and necrosis. Cyclin D1 expression is often found deregulated in cancerous cells, particularly in those of the breast and the head/neck. …
Metadata
Title
Potential role of cyclin D1in DNA damage response
Authors
N Suwaki
DJ Mann
Publication date
01-11-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1568

Other articles of this Special Issue 2/2006

Breast Cancer Research 2/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine